Liposomal Mucosal Vaccine Development Service

Mucosal-Specific Liposome Composition: We formulate liposomal systems with optimized lipid compositions tailored for effective mucosal delivery. This includes the selection of lipids with ideal characteristics such as optimal surface charge, size, and biocompatibility to enhance adhesion and uptake at mucosal surfaces.

• Cationic Lipid and Anionic Lipid Mixtures: Our team strategically uses cationic and anionic lipids, which have shown enhanced ability to interact with mucosal tissues, ensuring better adhesion and antigen uptake. These formulations increase the stability and persistence of the liposomes at the site of administration.
• Mucosal Surface Targeting: We optimize lipid formulations to achieve targeted delivery to mucosal-associated lymphoid tissues (MALT), including the nasal and gastrointestinal tracts. These are critical sites for initiating immune responses. By selecting specific lipids and surface coatings, such as chitosan or mannose, we increase the liposome's affinity for mucosal tissues.

Antigen Encapsulation & Release Profile: We engineer liposomes to encapsulate antigens effectively while ensuring slow, controlled release at the site of mucosal delivery. Our liposomal formulations ensure that the antigen is protected during transit through the mucosal barrier and is gradually released to stimulate a sustained immune response.

• Custom PH-Responsive Liposome Service: For oral or gastrointestinal mucosal vaccines, we use pH-sensitive liposomal formulations that can withstand acidic conditions in the stomach and release the antigen at a specific pH level, ensuring stability and effective delivery to intestinal mucosa.

We apply advanced liposome targeted modification services, using biocompatible polymers or ligands that promote better adhesion to mucosal tissues.

• Custom Peptide-Functionalized Liposome Service: Our Custom Peptide-Functionalized Liposome Service enhances mucosal vaccine targeting by incorporating peptides like TAT, RGD, and KLK. TAT peptides improve cellular penetration, RGD peptides target integrins on immune cells, and KLK peptides enhance interaction with mucosal tissues. This functionalization boosts antigen uptake by dendritic cells and macrophages, optimizing both local and systemic immune responses for more effective mucosal immunization.
• Polymer-Modified Liposomes Synthesis Service: Our Polymer-Modified Liposomes Synthesis Service enhances vaccine stability and delivery using polymers such as PEG, PLGA, and chitosan. PEG improves circulation time, PLGA offers controlled release, and chitosan enhances mucosal adhesion and immune response. These modifications ensure more stable, targeted, and effective liposomal vaccines with prolonged antigen delivery at mucosal surfaces.

Our service includes a rigorous testing protocol designed to assess the thermal stability of your vaccine under a range of real-world conditions. Key testing features include:

• Protection of Sensitive Antigens: Liposomes are particularly valuable for protecting fragile antigens (e.g., proteins, nucleic acids) from enzymatic degradation in the mucosal environment. Our liposomal formulations ensure that these antigens remain intact and functional by encapsulating them in highly stable, biocompatible lipid bilayers.
• Multi-layer Liposomes for Enhanced Stability: For certain antigen formulations that require additional protection, we use multilamellar liposomes, providing multiple layers to further safeguard the antigen during delivery to mucosal surfaces, reducing the likelihood of degradation before the antigen reaches its target.

Our liposomal formulations are designed for optimized delivery through nasal and oral routes, two of the most effective non-invasive mucosal pathways. Liposomal encapsulation enhances the stability and penetrability of the vaccine in these environments.

• Nasal Vaccine Development: Liposomes formulated for nasal vaccines ensure that the antigen is effectively delivered to the nasopharyngeal region, where the immune response can be robustly activated.
• Oral Vaccine Development: For oral vaccines, we provide liposomal formulations that protect the vaccine from acidic conditions in the stomach while facilitating the controlled release of the antigen in the intestinal mucosa.